Emerging studies suggest this peptide, a dual agonist targeting both incretin and another hormone, could provide a notable advancement for weight treatment. Early clinical trials have indicated impressive reductions in abdominal fat , conceivably outperforming existing weight-loss medications . Nevertheless , further assessment is needed to fully d